Takeda Pharmaceutical (TAK) Debt to Equity (2018 - 2025)
Historic Debt to Equity for Takeda Pharmaceutical (TAK) over the last 8 years, with Q3 2025 value amounting to $0.69.
- Takeda Pharmaceutical's Debt to Equity changed N/A to $0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.69, marking a year-over-year change of. This contributed to the annual value of $0.65 for FY2025, which is 219.62% down from last year.
- As of Q3 2025, Takeda Pharmaceutical's Debt to Equity stood at $0.69.
- Takeda Pharmaceutical's Debt to Equity's 5-year high stood at $0.94 during Q1 2021, with a 5-year trough of $0.65 in Q1 2025.
- Over the past 5 years, Takeda Pharmaceutical's median Debt to Equity value was $0.71 (recorded in 2024), while the average stood at $0.75.
- Its Debt to Equity has fluctuated over the past 5 years, first crashed by 2311.46% in 2021, then soared by 406.52% in 2024.
- Quarter analysis of 5 years shows Takeda Pharmaceutical's Debt to Equity stood at $0.88 in 2021, then fell by 18.74% to $0.72 in 2022, then increased by 0.26% to $0.72 in 2023, then fell by 0.48% to $0.71 in 2024, then dropped by 3.8% to $0.69 in 2025.
- Its Debt to Equity stands at $0.69 for Q3 2025, versus $0.68 for Q2 2025 and $0.65 for Q1 2025.